Pharmacology

Merck Serono, a division of Merck, has donated its 100 millionth praziquantel tablet to the World Health Organization (WHO).


The European Commission has approved  Abbott's HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. 


A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists have combined two already approved pharmaceutical substances with each other using a chemical linker structure.


Some people have a distinct, disabling sleep disorder called "primary hypersomnia" - they regularly sleep more than 70 hours per week and have difficulties awakening.

Even when awake, they still have reaction times comparable to someone who has been awake all night. Their sleepiness often interferes with work or school attendance, and conventional treatments such as stimulants bring little relief.


An enzyme used in nature can make powerful chemicals as diverse as catnip and a cancer drug, vinblastine, which opens up the prospect of producing these chemicals cheaply and efficiently.


The All Wales Strategic Medical Group (AWSMG) has approved Zebinix(R) (eslicarbazepine acetate) for the treatment of partial seizures in highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations.

Eslicarbazepine acetate is licensed in Europe as an adjunctive therapy for adults with partial-onset seizures with or without secondary generalization. 


There's been plenty of research showing that when people inhale oxytocin, they tend to have more positive social behavior: trust, generosity,empathy and communication. But if taking one whiff of oxytocin can make younicer, will taking oxytocin regularly keep you nicer? If you take a biggerdose, will it make you even nicer?

U.C. Davis researchers wanted to find out the long-term effects of taking oxytocin, so they studied prairie voles, the monogamous rodents that first demonstrated the positive social effects of this brain chemical.

The U.C. Davis research team, led by Karen L. Bales, treateda group of 89 male prairie voles with low, medium or high doses of inhaled oxytocin. The medium dose was roughly equivalent to the amount given to human subjects in lab studies.

New data from the RELY-ABLE study have provided additional support to the safety profile and efficacy of Pradaxa(R) (dabigatran etexilate) for stroke prevention in patients with nonvalvular atrial fibrillation (AF) over a period in excess of 2 years.[*][1]

The new long-term results presented at the American Heart Association's (AHA) Scientific Sessions, are consistent with the findings from the RE-LY trial[*]. The rates of stroke and haemorrhage observed during an additional 2.3 years of blinded follow-up in RELY-ABLE correspond to the initial RE-LY results, with the benefit of both doses of dabigatran etexilate sustained throughout the study's duration.[1]-[3] 



Winston Churchill liked his chocolate and he liked it rich and dark. At least that is what Hitler must have been convinced of as he decided to lure the British prime minister not with cigars but with dark chocolate. Churchill barely escaped his death by chocolate and went on to win the Nobel Prize in literature.

Coincidence?